Aoki J, Iguchi Y, Urabe T, et al. - In an investigator-initiated, prospective, multicenter (34 hospitals in Japan), randomized, open-label, and aspirin-controlled trial, researchers assessed patients with noncardioembolic stroke on whether antiplatelet dual therapy (aspirin plus cilostazol) is safe and effective within 48 hours of symptom onset. In a random manner, participants were assigned to receive combination therapy with aspirin 81 to 200 mg plus cilostazol 200 mg (dual group) and single therapy with aspirin 81 to 200 mg (aspirin group) for 14 days. Thereafter, cilostazol 200 mg was received by all patients for 3 months. Participants were observed between May 2011 and June 2017. Findings revealed the safety of dual antiplatelet therapy using cilostazol and aspirin, however, this therapy failed to attenuate the rate of short-term neurological worsening.